SLC18A1 Antibody

What is SLC18A1 and what is its basic function in human physiology?

SLC18A1, also known as Vesicular Monoamine Transporter 1 (VMAT1) or Chromaffin Granule Amine Transporter (CGAT), is a protein that functions as an electrogenic antiporter. It exchanges cationic monoamines with intravesicular protons across the membrane of secretory and synaptic vesicles . The protein's primary function is to accumulate cytosolic monoamines into vesicles, utilizing the proton gradient maintained across vesicular membranes .

SLC18A1's proper function is essential for the correct activity of monoaminergic systems, which have been implicated in several human neuropsychiatric disorders . The protein is predominantly expressed in neuroendocrine tissues and has a calculated molecular weight of approximately 49-56 kDa .

What specific applications are SLC18A1 antibodies validated for in research?

SLC18A1 antibodies have been validated for multiple research applications, with specific parameters depending on the antibody clone. Based on the literature, the primary validated applications include:

Validation data typically shows detection in human cell lines including HeLa, A549, HepG2, and rat C6 cells .

How should SLC18A1 antibodies be stored and reconstituted for optimal performance?

Proper storage and reconstitution of SLC18A1 antibodies is crucial for maintaining their functionality:

Storage recommendations:

• Store lyophilized antibodies at -20°C for up to one year from date of receipt

• After reconstitution, store at 4°C for one month or aliquot and store at -20°C for up to six months

• Avoid repeated freeze-thaw cycles as they can compromise antibody integrity

Reconstitution protocol:

• For lyophilized antibodies (e.g., from Boster Bio), add 0.2 ml of distilled water to yield a concentration of 500 μg/ml

• For antibodies in PBS buffer with additives (e.g., ProSci Inc.), add 50 μL of distilled water to reach a final concentration of 1 mg/mL

• Some liquid formulations (e.g., Proteintech's 20340-1-AP) come in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3, requiring no reconstitution

Storage buffers may contain stabilizers like trehalose, NaCl, Na₂HPO₄, and NaN₃ to maintain antibody integrity .

What are the reactivity profiles of commonly used SLC18A1 antibodies?

SLC18A1 antibodies vary in their cross-reactivity with species, with most research-grade antibodies being raised against human SLC18A1. The reactivity profiles based on the search results show:

How can I validate SLC18A1 antibody specificity in my experimental system?

Validating antibody specificity is crucial for reliable research outcomes. For SLC18A1 antibodies, consider these validation approaches:

Western blot validation:

• Use positive controls: Human cell lines with known SLC18A1 expression (Hela, A549, U-87MG, A431, HL-60, K562)

• Compare observed molecular weight (typically 56 kDa) with calculated weight (49229 MW)

• Include negative controls: Use cell lines with minimal SLC18A1 expression or tissues known not to express the protein

• Peptide competition assay: Pre-incubate antibody with immunizing peptide to confirm signal specificity

Immunohistochemistry validation:

• Compare staining patterns with literature-reported SLC18A1 localization (neuroendocrine tissues)

• Perform parallel staining with two different SLC18A1 antibodies recognizing different epitopes

• Include appropriate negative controls (omitting primary antibody, isotype controls)

• For neuropsychiatric research, validate in relevant tissues (adrenal medulla, brain regions)

Flow cytometry validation:

• Use overlay histograms showing cells stained with SLC18A1 antibody versus isotype control

• Include unlabelled sample without primary and secondary antibody as blank control

• Confirm cell permeabilization effectiveness, as SLC18A1 is primarily located in vesicular membranes

The Western blot conditions from validated studies include: SDS-PAGE gel at 70V/90V, 50μg sample under reducing conditions, nitrocellulose transfer at 150mA, blocking with 5% non-fat milk, and primary antibody incubation at 0.5μg/mL overnight at 4°C .

What role does SLC18A1 play in neuropsychiatric disorders, and how can antibodies help investigate this relationship?

SLC18A1/VMAT1 has significant implications for neuropsychiatric research due to its associations with several disorders:

Neuropsychiatric associations:

• Bipolar I disorder: Variations in SLC18A1 gene (particularly Thr136Ile polymorphism) show significant association (p=0.003; OR=1.34; 95% CI: 1.11–1.62)

• Schizophrenia: SLC18A1 maps to a shared bipolar disorder/schizophrenia susceptibility locus on chromosome 8p21-22

• Anxiety-related personality traits: Human-unique variant (rs1390938, Thr136Ile) shows relatively high frequency (20-61%) in non-African populations

• Barbiturate abuse and adrenal neuroblastoma are also associated with SLC18A1

Research applications with antibodies:

• Comparative expression studies: Use immunohistochemistry to compare SLC18A1 expression in postmortem brain tissue from patients with neuropsychiatric disorders versus controls

  • Protocol: Heat-mediated antigen retrieval in EDTA buffer (pH 8.0), blocking with 10% goat serum, primary antibody incubation at 1μg/ml overnight at 4°C

• Genetic variant impact assessment: Investigate how SLC18A1 polymorphisms affect protein expression and localization

  • Notable variants: Thr4Pro, Thr98Ser, Thr136Ile, Val392Leu

  • Thr136Ile has been shown to influence transport activity in vitro

• Drug mechanism studies: Examine effects of psychiatric medications on SLC18A1 expression and function

  • SLC18A1 is a target for drugs including reserpine and tetrabenazine

Research has shown that increased expression of SLC18A1 is associated with significantly increased survival in patients with adenocarcinoma (p=0.0058) , suggesting broader implications beyond neuropsychiatric conditions.

What are the key considerations for optimizing immunohistochemical detection of SLC18A1 in different tissue types?

Optimizing immunohistochemical detection of SLC18A1 requires tissue-specific considerations due to its variable expression patterns:

Critical optimization parameters:

• Antigen retrieval methods:

  • For pancreatic cancer tissue: Heat-mediated antigen retrieval in EDTA buffer (pH 8.0)

  • For rectal cancer tissue: Same EDTA buffer protocol as above

  • For placenta tissue: Two options are recommended:
    a) TE buffer pH 9.0 (primary recommendation)
    b) Citrate buffer pH 6.0 (alternative approach)

• Blocking and antibody conditions:

  • Block with 10% goat serum to minimize background

  • Primary antibody concentration: 1μg/ml (optimal for Boster Bio antibody)

  • Incubation: Overnight at 4°C for maximum sensitivity

  • Secondary detection: Biotinylated goat anti-rabbit IgG (30 minutes at 37°C)

  • Visualization: Strepavidin-Biotin-Complex with DAB as chromogen

• Tissue-specific considerations:

  • Neuroendocrine tissues: Require lower antibody dilutions (1:20-1:50)

  • Brain tissue: May need longer primary antibody incubation times

  • Cancer tissues: Higher background may necessitate more stringent washing

  • Placenta: Shows robust expression and serves as a positive control

• Controls:

  • Positive controls: Human pancreatic and rectal cancer tissues show detectable expression

  • Negative controls: Omit primary antibody but maintain all other steps

For lung cancer research, SLC18A1 expression has specific prognostic value - increased expression is associated with significantly increased survival in adenocarcinoma patients (p=0.0058) but not in squamous carcinoma patients (p=0.96) .

How does genetic variation in SLC18A1 affect antibody selection and experimental design?

Genetic polymorphisms in SLC18A1 can significantly impact antibody selection and experimental design, particularly for neuropsychiatric research:

Key SLC18A1 variants and their implications:

Antibody selection considerations:

• Epitope location:

  • Select antibodies whose epitopes do not overlap with common polymorphic sites

  • For populations with high frequency of specific variants, choose antibodies binding to conserved regions

  • When studying specific variants, select antibodies that can distinguish between variants

• Experimental design recommendations:

  • Genotype samples for known SLC18A1 variants before antibody-based experiments

  • Include variant-specific positive controls

  • For populations with diverse genetic backgrounds, validate antibody performance across genotypes

  • Consider using multiple antibodies recognizing different epitopes

• Special considerations for neuropsychiatric research:

  • The Thr136Ile variant shows balancing selection in non-African populations and originated around 100,000 years ago

  • This variant influences SLC18A1 transport activity in vitro , potentially affecting protein conformation

  • For cross-population studies, account for population differences in variant frequencies

Research indicates that understanding SLC18A1 genetic variation is particularly important when designing experiments related to monoaminergic neurotransmission in psychiatric disorders, as these variants may have functional consequences on protein activity and drug responses .

What are the most reliable positive and negative controls for SLC18A1 antibody validation?

Establishing appropriate controls is essential for validating SLC18A1 antibody performance across different experimental systems:

Recommended positive controls:

• Cell lines with confirmed expression:

  • Human: HeLa, A549, U-87MG, A431, HL-60, K562

  • Rat: C6 cells

• Tissue samples with known expression:

  • Human pancreatic cancer tissue

  • Human rectal cancer tissue

  • Human placenta tissue

  • Adrenal medulla (high endogenous expression)

  • Neuroendocrine tumors

• Recombinant protein controls:

  • E.coli-derived human VMAT1/SLC18A1 recombinant protein (Position: M1-E510)

  • Synthetic peptide standards corresponding to target epitopes

Recommended negative controls:

• Technical controls:

  • Primary antibody omission

  • Isotype-matched irrelevant antibody (e.g., rabbit IgG used at same concentration)

  • Secondary antibody only

  • Peptide competition (pre-incubation of antibody with immunizing peptide)

• Biological controls:

  • Tissues known to lack SLC18A1 expression

  • Cell lines with confirmed absence of SLC18A1

  • SLC18A1 knockout models (when available)

  • SLC18A1-negative regions within positively-staining tissues (internal control)

Flow cytometry-specific controls:

• Isotype control antibody (e.g., rabbit IgG at 1μg/1x10^6 cells)

• Unlabelled sample without incubation with primary and secondary antibody

• Single-stained samples for compensation in multicolor experiments

For neuropsychiatric research, consider that lifelong never-smokers with lung cancer have the highest SLC18A1 expression , which may serve as a useful reference point for expression studies in other contexts.

How can I distinguish between SLC18A1 (VMAT1) and its paralog SLC18A2 (VMAT2) in experimental settings?

Distinguishing between the two vesicular monoamine transporter paralogs is critical for accurate research interpretation:

Key differences between SLC18A1 and SLC18A2:

Experimental approaches to distinguish these paralogs:

• Antibody selection:

  • Use antibodies raised against non-conserved regions between SLC18A1 and SLC18A2

  • Verify specificity through Western blot against recombinant proteins of both transporters

  • Perform peptide competition assays with specific peptides from each paralog

• RT-PCR discrimination:

  • Design primers targeting non-conserved regions

  • Perform quantitative PCR with paralog-specific probes

  • Include positive controls for each paralog

• Immunohistochemical distinction:

  • Perform sequential staining with antibodies against each paralog

  • Use different chromogens or fluorophores for clear visualization

  • Analyze tissue distribution patterns (SLC18A1 predominantly in peripheral neuroendocrine tissues)

• Functional discrimination:

  • Differential sensitivity to inhibitors (e.g., reserpine affects both, but with different potencies)

  • Transport kinetics differences

  • Response to cellular signaling pathways

When investigating monoamine-related disorders, it's important to note that SLC18A1 is an important paralog of SLC18A2 , and their distinct but overlapping functions contribute to the complexity of monoaminergic systems in psychiatric and neurological disorders.